Stoke Therapeutics, Inc. (STOK) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
STOK Revenue Growth
Revenue Breakdown (FY 2025)
STOK's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
STOK Revenue Analysis (2017–2025)
As of May 8, 2026, Stoke Therapeutics, Inc. (STOK) generated trailing twelve-month (TTM) revenue of $32.1 million, reflecting significant decline in growth of -96.1% year-over-year. The most recent quarter (Q1 2026) recorded $6.2 million in revenue, up 344.3% sequentially.
Looking at the longer-term picture, STOK's historical revenue data shows a 3-year CAGR of +145.9%. The company achieved its highest annual revenue of $184.4 million in 2025, representing a new all-time high.
Revenue diversification analysis shows STOK's business is primarily driven by License (71%), and Service (29%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), ARVN (-0.3% YoY), and IONS (+47.5% YoY), STOK has underperformed the peer group in terms of revenue growth. Compare STOK vs ACAD →
STOK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| STOKCurrent | $32M | -96.1% | - | -11.2% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% |
STOK Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $184.4M | +404.5% | $184.4M | 100.0% | $-20,590,000 | -11.2% |
| 2024 | $36.6M | +316.3% | $36.6M | 100.0% | $-101,372,000 | -277.3% |
| 2023 | $8.8M | -29.2% | $8.8M | 100.0% | $-114,773,000 | -1307.2% |
| 2022 | $12.4M | - | $12.4M | 100.0% | $-104,356,000 | -841.2% |
| 2021 | $0 | - | $0 | - | $-86,065,000 | - |
| 2020 | $0 | - | $-1,926,000 | - | $-53,044,000 | - |
| 2019 | $0 | - | $-450,000 | - | $-35,678,000 | - |
| 2018 | $0 | - | $-214,000 | - | $-12,781,000 | - |
| 2017 | $0 | - | $-113,000 | - | $-5,554,000 | - |
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STOK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSTOK — Frequently Asked Questions
Quick answers to the most common questions about buying STOK stock.
Is STOK's revenue growth accelerating or slowing?
STOK revenue declined -96.1% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $32M. This reverses the prior growth trend.
What is STOK's long-term revenue growth rate?
Stoke Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -96.1% is below this long-term average.
How is STOK's revenue distributed by segment?
STOK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.